Insulin resistance and Parkinson’s disease: A new target for disease modification?
详细信息 查看全文
- 作者：D. Athauda ; d.athauda@ucl.ac.uk" class="auth_mail" title="E-mail the corresponding author (Dr.) ; T. Foltynie t.foltynie@ucl.ac.uk" class="auth_mail" title="E-mail the corresponding author (Dr.)
- 关键词：AB ; amyloid beta ; AD ; Alzheimer&rsquo ; s disease ; AGE ; advanced glycation end products ; AKT ; protein kinase B ; BAD ; Bcl 2 antagonist of death ; BBB ; blood brain barrier ; Bcl-2 ; B-cell lymphoma 2 ; Bcl-XL ; B-cell lymphoma extra large ; Bim ; Bcl-2 interacting mediator of death ; cAMP ; cyclic adenosine monophosphate ; CREB ; cAMP response element-binding protein ; CNS ; central nervous system ; CSF ; cerebrospinal fluid ; DA ; dopamine ; DLB ; dementia with lewy bodies ; DPP-4 ; dipeptidyl peptidase 4 ; ERK ; extrace
- 刊名：Progress in Neurobiology
- 出版年：2016
- 出版时间：October-November 2016
- 年：2016
- 卷：145-146
- 期：Complete
- 页码：98-120
- 全文大小：2146 K
文摘
- •
Parkinson’s disease and Type 2 diabetes share many common pathophysiological mechanisms.
- •
Insulin signalling modulates a number of cellular processes found to be disrupted in Parkinson’s disease.
- •
A process analogous to peripheral insulin resistance may occur in the brain and contribute to Parkinson’s disease pathology.
- •
20">Using insulin sensitising drugs to restore insulin signalling may represent a novel therapeutic strategy in Parkinson’s disease.